Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

New patient-reported outcomes at WCLC 2025 confirm preserved quality of life with the FDA-approved perioperative nivolumab regimen.

CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC
Image

Overview

  • An exploratory analysis from the phase 3 CheckMate 77T trial found no compromise in health-related quality of life with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab.
  • In stage III N2 disease, nivolumab reduced the risk of quality-of-life deterioration by about half, with hazard ratios ranging from 0.45 to 0.53 across NSCLC-SAQ and EQ-5D-3L VAS measures.
  • Time to definitive deterioration was prolonged with nivolumab, reaching 44.5 months versus 31.4 months by NSCLC-SAQ and 44.5 months versus 35.7 months by EQ-5D-3L VAS.
  • Benefits extended to surgical subgroups, including patients who underwent simple lobectomy (NSCLC-SAQ HR 0.41) or achieved complete resection (NSCLC-SAQ HR 0.48), with supportive EQ-5D-3L VAS findings.
  • PRO completion rates exceeded 90% across most timepoints, and scores were generally stable through follow-up aside from expected short-term dips around surgery.